8 research outputs found
Increase of the Adiponectin/Leptin Ratio in Patients with Obesity and Type 2 Diabetes after Roux-en-Y Gastric Bypass
Bariatric surgery remains the most effective option for achieving important and sustained weight loss. We explored the effects of Roux-en-Y gastric bypass (RYGB) on the circulating levels of adiponectin, leptin, and the adiponectin/leptin (Adpn/Lep) ratio in patients with obesity and type 2 diabetes (T2D). Twenty-five T2D volunteers undergoing RYGB were included in the study, and further subclassified as patients that responded or not to RYBG, regarding remission of T2D. Anthropometric and biochemical variables were evaluated before and after RYGB. Obese patients with T2D exhibited an increase (p < 0.0001) in the Adpn/Lep ratio after RYGB. Changes in the Adpn/Lep ratio correlated better with changes in anthropometric data (p < 0.001) than with the variations of adiponectin or leptin alone. Multiple regression analysis revealed that the change in the Adpn/Lep ratio in patients with T2D was an independent predictor of the changes in body mass index (p < 0.001) and body fat percentage (p = 0.022). However, the Adpn/Lep ratio did not differ between individuals with or without T2D remission after RYGB. In summary, the current study demonstrated that after weight and body fat loss following RYGB, the Adpn/Lep ratio increased in patients with obesity and T2D
GLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patients
Objective: Glucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose
improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically-induced
type 2 diabetes (T2D) improvement and its capacity to regulate human adipocyte inflammation.
Methods: Basal circulating concentrations of GLP-1 as well as during an oral glucose tolerance test
(OGTT) were measured in lean and obese volunteers with and without T2D (n = 93). In addition,
GLP-1 levels were determined before and after weight loss achieved by Roux-en-Y gastric bypass
(RYGB) (n = 77). The impact of GLP-1 on inflammation signalling pathways was also evaluated.
Results: We show that the reduced (p < 0.05) circulating levels of GLP-1 in obese T2D patients
increased (p < 0.05) after RYGB. The area under the curve was significantly lower in obese patients
with (p < 0.01) and without (p < 0.05) T2D compared to lean volunteers while obese patients with
T2D exhibited decreased GLP-1 levels at baseline (p < 0.05) and 120 min (p < 0.01) after the OGTT.
Importantly, higher (p < 0.05) pre-operative GLP-1 concentrations were found in patients with
T2D remission after RYGB. We also revealed that exendin-4, a GLP-1 agonist, downregulated the
expression of inflammation-related genes (IL1B, IL6, IL8, TNF) and, conversely, upregulated the
mRNA levels of ADIPOQ in human visceral adipocytes. Furthermore, exendin-4 blocked (p < 0.05)
LPS-induced inflammation in human adipocytes via downregulating the expression and secretion of
key inflammatory markers. Conclusions: Our data indicate that GLP-1 may contribute to glycemic
control and exert a role in T2D remission after RYGB. GLP-1 is also involved in limiting inflammation
in human visceral adipocytes
Increased obesity-associated circulating levels of the extracellular matrix proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C are associated with colon cancer
Excess adipose tissue represents a major risk factor for the development of colon cancer with inflammation and extracellular matrix (ECM) remodeling being proposed as plausible mechanisms. The aim of this study was to investigate whether obesity can influence circulating levels of inflammation-related extracellular matrix proteins in patients with colon cancer (CC), promoting a microenvironment favorable for tumor growth.
Methods
Serum samples obtained from 79 subjects [26 lean (LN) and 53 obese (OB)] were used in
the study. Enrolled subjects were further subclassified according to the established diagnostic
protocol for CC (44 without CC and 35 with CC). Anthropometricmeasurements as
well as circulating metabolites and hormoneswere determined. Circulating concentrations
of the ECM proteins osteopontin (OPN), chitinase-3-like protein 1 (YKL-40), tenascin C
(TNC) and lipocalin-2 (LCN-2) were determined by ELISA.
Results
Significant differences in circulating OPN, YKL-40 and TNC concentrations between the
experimental groups were observed, being significantly increased due to obesity (P<0.01)
and colon cancer (P<0.05). LCN-2 levels were affected by obesity (P<0.05), but no differences
were detected regarding the presence or not of CC. A positive association (P<0.05)
with different inflammatorymarkers was also detected.Conclusions
To our knowledge, we herein show for the first time that obese patients with CC exhibit
increased circulating levels of OPN, YKL-40 and TNC providing furtherevidence for the
influence of obesity on CC development via ECM proteins, representing promising diagnostic
biomarkers or target molecules for therapeutics
Increase of the Adiponectin/Leptin Ratio in Patients with Obesity and Type 2 Diabetes after Roux-en-Y Gastric Bypass
Bariatric surgery remains the most effective option for achieving important and sustained weight loss. We explored the effects of Roux-en-Y gastric bypass (RYGB) on the circulating levels of adiponectin, leptin, and the adiponectin/leptin (Adpn/Lep) ratio in patients with obesity and type 2 diabetes (T2D). Twenty-five T2D volunteers undergoing RYGB were included in the study, and further subclassified as patients that responded or not to RYBG, regarding remission of T2D. Anthropometric and biochemical variables were evaluated before and after RYGB. Obese patients with T2D exhibited an increase (p < 0.0001) in the Adpn/Lep ratio after RYGB. Changes in the Adpn/Lep ratio correlated better with changes in anthropometric data (p < 0.001) than with the variations of adiponectin or leptin alone. Multiple regression analysis revealed that the change in the Adpn/Lep ratio in patients with T2D was an independent predictor of the changes in body mass index (p < 0.001) and body fat percentage (p = 0.022). However, the Adpn/Lep ratio did not differ between individuals with or without T2D remission after RYGB. In summary, the current study demonstrated that after weight and body fat loss following RYGB, the Adpn/Lep ratio increased in patients with obesity and T2D
Increased obesity-associated circulating levels of the extracellular matrix proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C are associated with colon cancer
Excess adipose tissue represents a major risk factor for the development of colon cancer with inflammation and extracellular matrix (ECM) remodeling being proposed as plausible mechanisms. The aim of this study was to investigate whether obesity can influence circulating levels of inflammation-related extracellular matrix proteins in patients with colon cancer (CC), promoting a microenvironment favorable for tumor growth.
Methods
Serum samples obtained from 79 subjects [26 lean (LN) and 53 obese (OB)] were used in
the study. Enrolled subjects were further subclassified according to the established diagnostic
protocol for CC (44 without CC and 35 with CC). Anthropometricmeasurements as
well as circulating metabolites and hormoneswere determined. Circulating concentrations
of the ECM proteins osteopontin (OPN), chitinase-3-like protein 1 (YKL-40), tenascin C
(TNC) and lipocalin-2 (LCN-2) were determined by ELISA.
Results
Significant differences in circulating OPN, YKL-40 and TNC concentrations between the
experimental groups were observed, being significantly increased due to obesity (P<0.01)
and colon cancer (P<0.05). LCN-2 levels were affected by obesity (P<0.05), but no differences
were detected regarding the presence or not of CC. A positive association (P<0.05)
with different inflammatorymarkers was also detected.Conclusions
To our knowledge, we herein show for the first time that obese patients with CC exhibit
increased circulating levels of OPN, YKL-40 and TNC providing furtherevidence for the
influence of obesity on CC development via ECM proteins, representing promising diagnostic
biomarkers or target molecules for therapeutics
GLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patients
Objective: Glucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose
improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically-induced
type 2 diabetes (T2D) improvement and its capacity to regulate human adipocyte inflammation.
Methods: Basal circulating concentrations of GLP-1 as well as during an oral glucose tolerance test
(OGTT) were measured in lean and obese volunteers with and without T2D (n = 93). In addition,
GLP-1 levels were determined before and after weight loss achieved by Roux-en-Y gastric bypass
(RYGB) (n = 77). The impact of GLP-1 on inflammation signalling pathways was also evaluated.
Results: We show that the reduced (p < 0.05) circulating levels of GLP-1 in obese T2D patients
increased (p < 0.05) after RYGB. The area under the curve was significantly lower in obese patients
with (p < 0.01) and without (p < 0.05) T2D compared to lean volunteers while obese patients with
T2D exhibited decreased GLP-1 levels at baseline (p < 0.05) and 120 min (p < 0.01) after the OGTT.
Importantly, higher (p < 0.05) pre-operative GLP-1 concentrations were found in patients with
T2D remission after RYGB. We also revealed that exendin-4, a GLP-1 agonist, downregulated the
expression of inflammation-related genes (IL1B, IL6, IL8, TNF) and, conversely, upregulated the
mRNA levels of ADIPOQ in human visceral adipocytes. Furthermore, exendin-4 blocked (p < 0.05)
LPS-induced inflammation in human adipocytes via downregulating the expression and secretion of
key inflammatory markers. Conclusions: Our data indicate that GLP-1 may contribute to glycemic
control and exert a role in T2D remission after RYGB. GLP-1 is also involved in limiting inflammation
in human visceral adipocytes